ARIMIDEX Gains Full FDA Approval for Adjuvant Treatment of Hormone Receptor-Positive Early Breast Cancer in Postmenopausal Women
19th Sep 2005, 17:35 GMT
ARIMIDEX is the only aromatase inhibitor with disease-free survival proven superior to tamoxifen in the primary adjuvant setting